GlassScriptPhysician profile
Reenal Rajit Patel
NPI 1427218775
$43,511.49
in general payments reported to CMS, 2019-2025
43 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,616 · 2020: $3,205 · 2021: $1,601 · 2022: $6,795 · 2023: $5,090 · 2024: $1,788 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $7,546 · Travel and Lodging: $1,121 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,513.82 |
| Food and Beverage | $7,546.34 |
| Travel and Lodging | $1,120.98 |
| Education | $112.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $15,714.16 | 2019-2025 | Dupixent |
| Genzyme Corporation | $13,254.69 | 2019-2025 | |
| Kaleo, INC. | $4,361.96 | 2019-2025 | Auvi-Q |
| Glaxosmithkline, LLC. | $2,291.53 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,543.75 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Optinose US, INC. | $942.78 | 2019-2025 | |
| Abbott Laboratories | $770.31 | 2025 | Triclip |
| Novartis Pharmaceuticals Corporation | $649.53 | 2019-2025 | |
| Pfizer INC. | $490.70 | 2019-2025 | |
| Abiomed | $431.16 | 2019-2021 | |
| Amgen INC. | $371.11 | 2022-2025 | Tezspire |
| Incyte Corporation | $360.19 | 2021-2025 | Opzelura |
| Alk-Abello, INC | $211.84 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Biocryst US Sales Co., LLC | $177.86 | 2023-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $174.07 | 2025 | Neffy |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $157.60 | 2022-2025 | Adbry, Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.96 | 2019-2025 | Jardiance |
| Abbvie INC. | $148.71 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $138.20 | 2019-2022 | |
| Csl Behring | $119.88 | 2025 | Andembry |
| Celgene Corporation | $100.27 | 2024 | Zeposia |
| Janssen Pharmaceuticals, INC | $87.46 | 2022 | |
| Cvrx, INC. | $86.02 | 2020 | |
| Genentech USA, INC. | $81.39 | 2019-2025 | Xolair |
| Encore Dermatology INC. | $76.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.04 | 2021-2024 | Takhzyro |
| Lilly USA, LLC | $68.40 | 2024-2025 | Ebglyss |
| Pharming Healthcare, INC. | $51.87 | 2023-2024 | Ruconest |
| Blueprint Medicines Corporation | $51.30 | 2024 | Ayvakit |
| Portola Pharmaceuticals, LLC | $40.51 | 2019-2020 | |
| Galderma Laboratories, L.P. | $39.45 | 2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $38.92 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $37.04 | 2019-2022 | |
| Phadia US INC. | $33.71 | 2023 | Immunocap |
| Dermavant Sciences, INC. | $26.45 | 2024 | Vtama |
| Grifols USA, LLC | $25.41 | 2025 | Xembify |
| Merck Sharp & Dohme LLC | $24.33 | 2023 | |
| Mylan Specialty L.P. | $22.23 | 2019 | |
| Inari Medical, INC. | $19.53 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $19.52 | 2021 | |
| Hikma Pharmaceuticals USA | $17.16 | 2025 | Ryaltris |
| Eyevance Pharmaceuticals LLC | $16.98 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $12.80 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reenal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.